July 31, 2019

Commentary on use of PPIs and aspirin to prevent EAC

A thoughtful commentary on the strengths and weakness of the recent clinical trial of PPI and aspirin.

Commentary on use of PPIs and aspirin to prevent EAC

Nat Rev Clin Oncol. 2018 Dec;15(12):728-730. doi: 10.1038/s41571-018-0096-x.

Chemoprevention of Barrett’s oesophagus: a step closer with PPIs and aspirin.

Husain NS1,2, El-Serag HB3,4.

Chemoprevention for patients with Barrett’s oesophagus remains a
controversial topic. Results of the first randomized trial of chemoprevention
using a proton pump inhibitor with or without aspirin were recently reported.
We highlight strengths and weaknesses in the design of the trial and discuss
the clinical implications of the findings.